what would you tell week-1 you about non-peptide
Question in the title, detail here: what would you tell week-1 you about non-peptide.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Retitled to name the programme. It is what makes these threads findable in a year.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Phase 2 or phase 3?
Daily dosing, so what does the exposure profile look like across the day?
Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.
do not assume reconstitution intuitions apply, there is nothing to reconstitute
daily dosing, not weekly, so the exposure profile is different
the tolerability profile reads broadly similar to the class
Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.
a non-peptide agonist does not degrade the way a peptide does
no food and water restrictions is the practical difference people care about
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
Disagree.
flair_enthusiast is right that milligram comparisons across classes tell you nothing.
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
Went looking for independent testing on this and found essentially nothing, which was clarifying.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
the manufacturing story is genuinely different from the injectables
- 1no food and water restrictions is the practical difference people care about10 comments in this branch · started by u/phase_two_pete
- 2Oral semaglutide is a peptide co-formulated with an absorption enhancer and…9 comments in this branch · started by u/zeynep_ndiaye